Magos A L, Collins W P, Studd J W
Department of Gynaecology, Dulwich Hospital, London.
Br J Obstet Gynaecol. 1987 Dec;94(12):1192-8. doi: 10.1111/j.1471-0528.1987.tb02321.x.
The effects of subcutaneous oestradiol implants on ovarian activity were investigated in 14 ovulating premenopausal women. Treatment with either 100 mg or 150 mg oestradiol was combined with cyclical oral norethisterone from days 20 to 26 of the cycle to ensure regular withdrawal periods and prevent endometrial hyperplasia. Ovarian function was monitored by regular pelvic ultrasonography and urinalysis over a period of nine cycles. During the first three cycles after hormone implantation, follicular development continued in almost half the study group, but only one of the women in each treatment group showed signs of follicular rupture and luteinization. By the sixth cycle, over half the women given the lower dose of oestradiol were developing follicles, including a large functional cyst in one, but none of them ovulated. A further implant given early in the seventh cycle was associated with ovarian suppression in all cases. Both doses of implant elevated the excretion of oestrone-3-glucuronide compared to pretreatment. The contraceptive and therapeutic implications of these results are discussed.
对14名排卵的绝经前妇女研究了皮下植入雌二醇对卵巢活动的影响。在周期的第20至26天，将100毫克或150毫克雌二醇治疗与周期性口服炔诺酮联合使用，以确保有规律的撤退期并防止子宫内膜增生。在九个周期内，通过定期盆腔超声检查和尿液分析监测卵巢功能。在激素植入后的前三个周期中，几乎一半的研究组卵泡继续发育，但每个治疗组中只有一名妇女出现卵泡破裂和黄素化迹象。到第六个周期时，接受较低剂量雌二醇治疗的妇女中有一半以上正在发育卵泡，其中一人有一个大的功能性囊肿，但她们均未排卵。在第七周期早期再植入一次在所有病例中均导致卵巢抑制。与治疗前相比，两种剂量的植入物均使雌酮-3-葡萄糖醛酸苷排泄增加。讨论了这些结果的避孕和治疗意义。
